A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan

NCT01876745 · clinicaltrials.gov ↗

COMPLETED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Bleeding Disorder
Glanzmann's Disease

Interventions

DRUG: eptacog alfa (activated)

Sponsor

Novo Nordisk A/S